PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month

NEW YORK, September 25, 2024 – PRISM MediaWire – PRISM MarketView presents an exclusive Q&A with Dr. Michael Chancellor, Co-founder and Chief Medical Officer of Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO). In this interview, Dr. Chancellor provides insights into the company’s latest advancements in urological treatments, particularly in recognition of Urology Awareness Month, and discusses the significant progress made in the development of therapies for hemorrhagic cystitis (HC).

Lipella Pharmaceuticals, a clinical-stage biotechnology company, is focused on addressing serious urological conditions with significant unmet needs. Hemorrhagic cystitis, a painful and potentially life-threatening condition, has no FDA-approved treatments. “This is one of the most challenging conditions we treat, and current options are limited in their effectiveness,” Dr. Chancellor explained.

Key Milestones in Hemorrhagic Cystitis Treatment

Lipella’s lead candidate, LP-10, is an intravesical liposomal formulation of tacrolimus designed to treat moderate to severe hemorrhagic cystitis. Dr. Chancellor highlighted the promising results from a Phase 2a study, where 58% of patients showed significant improvement in symptoms, including reduced bleeding and bladder inflammation. “The localized delivery method of LP-10 has shown considerable promise, offering symptomatic relief while minimizing systemic absorption,” Dr. Chancellor added.

Looking Ahead: Phase 2b Trial in 2025

The company is set to initiate a larger Phase 2b trial for LP-10 in the first half of 2025. Dr. Chancellor emphasized the importance of this upcoming trial, stating, “We believe LP-10 has the potential to address the unmet need for an effective, FDA-approved treatment for hemorrhagic cystitis.”

In addition to its work on HC, Lipella is also expanding its pipeline. LP-310, a novel liposomal-tacrolimus oral rinse for Oral Lichen Planus (OLP), is currently being studied in a Phase 2a trial, with top-line results expected by the end of 2024. “We are committed to finding solutions for conditions that lack effective treatments, and our expanding pipeline reflects this mission,” Dr. Chancellor said.

The full Q&A with Dr. Michael Chancellor can be found at: https://prismmarketview.com/lipella-pharmaceuticals-advances-innovative-treatments-and-support-during-urology-awareness-month-2/

About Lipella Pharmaceuticals
Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Additionally, Lipella maintains a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. Lipella completed its initial public offering in December 2022. For more information, please visit www.lipella.com or LinkedIn

Forward-Looking Statements
This press release includes certain “forward-looking statements.” All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, future operations, financial position, prospects, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as “may,” “will,” “could,” “continue,” “would,” “should,” “potential,” “target,” “goal,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “predicts,” “expects,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, regional, national or global political, economic, business, competitive, market and regulatory conditions, and other factors. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax and financial advisors as to legal and related matters concerning the matters described herein.

About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.

PRISM MarketView does not provide investment advice.

Disclaimer
This communication was produced by PRISM MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is not a registered or licensed broker-dealer nor investment adviser. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security. PCG may be compensated by respective clients for publicizing information relating to its clients’ securities. See www.pcgadvisory.com/disclosures.

Contact:
PRISM MarketView
info@prismmarketview.com
646-863-6341

Source: PRISM MarketView

The post PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month first appeared on Prism Media Wire.